The Women’s Tennis Association (WTA) has introduced a new one-time genetic testing policy requiring athletes to undergo screening for the SRY gene, which is linked to male-typical sex development, ahead of the 2028 Los Angeles Olympics. The policy aims to determine biological sex while emphasizing that it does not seek to question gender identity, according to the WTA’s official statements.
Coco Gauff, a two-time Grand Slam champion, publicly addressed the policy following her opening-match win at the National Bank Open in Toronto. Gauff expressed support for the WTA’s intent to preserve fairness in women’s sports but criticized the policy’s potential to fuel animosity toward the transgender community. She described the issue as “a conversation that is very nuanced.”
Policy Details and Rationale
The WTA’s updated eligibility policy mandates a one-time cheek swab test to detect the presence of the SRY gene, which is located on the Y chromosome and plays a role in male sex development. The association stated that the testing is designed to assess biological sex without intending to disrespect or challenge an athlete’s gender identity.
The policy aligns with the International Olympic Committee’s (IOC) eligibility framework, which was revised in March 2024 following President Donald Trump’s executive order banning transgender athletes from competing in women’s sports. The IOC’s policy emphasizes the need to balance fair competition with inclusion, though specific enforcement mechanisms remain under discussion.
Gauff’s Stance: Fairness and Transgender Support
Gauff, speaking to reporters after her match, acknowledged the biological differences between male and female athletes while expressing concern over the politicization of the issue. She stated:
“I guess I kind of agree with trying to protect the fairness in women’s sports. But I also do not like the attack that it is creating—people who don’t really care, but just want to use this as a reason to attack the trans community. So I’m not really a big fan of that either.”
She reiterated her support for the transgender community, emphasizing that the debate has generated “a lot of animosity” toward transgender individuals. Gauff also noted the difficulty in framing her position without it being “spun” by external interpretations.
Scientific and Political Context
Dr. Andrew Sinclair, who discovered the SRY gene in the 1990s, has criticized the testing as an “overly simplistic” method for determining biological sex. In an opinion piece for the Murdoch Children’s Research Institute, Sinclair argued that genetic testing alone cannot fully account for intersex variations or other biological complexities.
The policy has also drawn attention from top WTA players, including Aryna Sabalenka, the world No. 1, who stated:
“I think it’s really important to keep the fairness in our tour. Biologically, men are way stronger than women, so I feel like it would not really be fair for women to compete against biological men.”
Broader Implications and Ongoing Debate
The WTA’s decision reflects a growing trend among sports governing bodies to address concerns about transgender participation in elite women’s sports. Similar policies have been adopted or proposed in track and field, swimming, and cycling, often citing the need to maintain competitive fairness.
Critics of such policies argue that they stigmatize transgender athletes and overlook the individual circumstances of each case. Advocacy groups, including Athlete Ally and Transgender Law Center, have condemned the testing as discriminatory and have called for alternative approaches that prioritize inclusion without compromising fairness.
The 2028 Olympics will serve as a key test case for how these policies are implemented and enforced globally. The WTA has indicated that it will review the policy’s effectiveness and may adjust its approach based on scientific and legal developments in the coming years.